Lung Cancer Clinical Trials in Michigan

Showing 341-360 of 566 trials

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

NCT00456261

This trial will look at 2 different drug combinations that have well known safety profiles and are known to be active against non small cell lung cancer and combine them with bevacizumab, an experimental drug that has shown effectiveness when added to other drug combinations for advanced non-small cell lung cancer. The primary objective in this study is to see how well this combination of drugs keeps the cancer from getting worse in this elderly population of non-small cell lung cancer patients.

Lung Cancer

SCRI Development Innovations, LLC110 participantsStarted Mar 2007

Anniston, Alabama, United States • Jonesboro, Arkansas, United States • Fort Myers, Florida, United States +15 more locations

COMPLETEDPhase 262 miles

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

NCT00600015

This trial will investigate the use of the newer targeted agents erlotinib and sorafenib in patients with stage IIIB or stage IV NSCLC who have received 1-2 prior chemotherapy regimens. Patients will be randomized to receive erlotinib (150 mg/day) and sorafenib (400 mg twice daily), or erlotinib (150 mg/day) and a placebo.

Non-Small Cell Lung Cancer

SCRI Development Innovations, LLC166 participantsStarted Feb 2008

Fort Myers, Florida, United States • Gainesville, Georgia, United States • Marietta, Georgia, United States +13 more locations

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Lung Cancer Trials in Other Cities

Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

PEN-866 in Patients With Advanced Solid Malignancies

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

A Study of LY3023414 in Participants With Advanced Cancer

A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer

Other Conditions in Michigan